Skip Navigation


NDT Advance Access originally published online on March 2, 2007
Nephrology Dialysis Transplantation 2007 22(5):1465-1467; doi:10.1093/ndt/gfm073
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/5/1465    most recent
gfm073v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Manenti, L.
Right arrow Articles by Vaglio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manenti, L.
Right arrow Articles by Vaglio, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-ß

Lucio Manenti1 and Augusto Vaglio2

1Division of Nephrology and Dialysis, Desenzano del Garda Hospital and 2Department of Clinical Medicine, Nephrology and Health Science, University of Parma, Parma, Italy

Correspondence and offprint requests to: Dr Lucio Manenti, Divisione di Nefrologia e Dialisi, Azienda Ospedaliera Desenzano del Garda, Via Montecroce 14, 25015 Desenzano d/G (BS), Italy. Email: lucio.manenti@aod.it

Keywords: anti-erythropoietin antibodies; disseminated intravascular coagulation; erythropoietin-ß; haemodialysis; pure red cell aplasia; rheumatoid arthritis

The first 150 words of the full text of this article appear below.



   Introduction
 
Pure red cell aplasia (PRCA) is a rare disorder that leads to severe anaemia with selective erythroblastopenia. PRCA may be secondary to drugs or infections with viruses such as parvovirus B19, which is known to cause the depletion of red blood cell precursors; in other cases, it is associated with thymoma, B– or T–cell lymphoproliferative disorders and other malignancies. In addition, PRCA is sometimes associated with autoimmune diseases (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) [1].

Although PRCA is very rare, the number of reported cases has dramatically increased in recent years, predominantly in patients with chronic kidney disease (CKD)–associated anaemia receiving subcutaneous injections of recombinant epoetin (rEpo) [1,2]. In this setting, PRCA is clearly associated with anti-erythropoietin antibodies (AEA), which have frequently been detected in the sera of affected patients and have been shown to be involved in the pathogenesis . . . [Full Text of this Article]



   Case report
 


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?